Uther Peptide Advances Structure-Defined Adalank R&D Program with Adamantane-Modified Research Sequence #Advertising
New York, New York--(Newsfile Corp. - November 3, 2026) - Uther Peptide today announced progress in the research and synthesis development of an adamantane-modified Adalank research reagent, establishing a defined structural specification centered on the sequence Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-Adam-NH₂. The development program marks a new step in the company's research-reagent platform, with emphasis on exact molecular structure, synthesis methodology, batch identity, and analytical verification... http://dlvr.it/TWBD1x